You take info and twist it to pump and throw in conjecture.Iplex's results were weak in Insmeds Phase 2 trial and the company dropped it as opposed to your "reading". REAL drugs and candidates are out there many many years and many manufacturers ahead.
Last week the FDA Approved a New Drug For HIV Lipodystrophy and Amylin is going to file a rolling NDA this year for its own Orphan Drug Candidate to treat Lipdystrophy There are many approved drugs that are approved and used to improve lipids triglycerides and weight control etc.Byetta is one of them and does a far better job than Iplex .
It's time to get real about Insmeds possibilities."reading " into a piece and making conclusions without a biotechnology or medical background is disingenuous.
Accugrowth, when you printed the WINROP Brazil abstract recently, I believe that you said that the December issue of Pediatrics would include an article that included some comments regarding iPLEX - is that what you posted? sometimes I have difficulty reading my own notes. Thanks.
Accugrowth.you do not know the subject matter - that is very clear.
Byetta which has been studied extensively since it was approved and marketed 5 years ago reported this past summer on the effect Byetta has on lipids triglycerides and weight control.(Duration 1 trial - if you care to stop posting ignorant remarks)
You also hype burns SIR and others - all indications that Insmed has dropped and Cancer that in 10 years has absolutely no capital venture interest Those are facts